beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00074104" target="_blank" >RIV/00159816:_____/20:00074104 - isvavai.cz</a>

Result on the web

<a href="https://n.neurology.org/content/95/24/e3257" target="_blank" >https://n.neurology.org/content/95/24/e3257</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/WNL.0000000000010943" target="_blank" >10.1212/WNL.0000000000010943</a>

Result language

angličtina

Original language name

beta-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies

Original language description

Objective In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that beta-amyloid and tau biomarker positivity increases with age, which is modified by APOE genotype and sex, and that there are isolated and synergistic associations with the clinical phenotype. Methods We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on beta-amyloid (A+) and tau (T+) biomarkers was determined by CSF beta-amyloid(1-42) and phosphorylated tau in the European cohort and by Pittsburgh compound B and AV-1451 PET in the Mayo Clinic cohort. Patients were stratified into 4 groups: A-T-, A+T-, A-T+, and A+T+. Results A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in APOE epsilon 4 carriers with age than in noncarriers. A+ was the main predictor of lower cognitive performance when considered together with T+. T+ was associated with a lower frequency of parkinsonism and probable REM sleep behavior disorder. There were no significant interactions between A+ and T+ in relation to the clinical phenotype. Conclusions Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. beta-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. Classification of evidence This study provides Class II evidence that in patients with probable DLB, beta-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neurology

ISSN

0028-3878

e-ISSN

—

Volume of the periodical

95

Issue of the periodical within the volume

24

Country of publishing house

US - UNITED STATES

Number of pages

12

Pages from-to

"E3257"-"E3268"

UT code for WoS article

000607315800022

EID of the result in the Scopus database

—